View Older Stories View More Recent Stories

Sep 21, 2020 10:21AM Exelixis (EXEL) Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Sep 21, 2020 10:20AM Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Sep 19, 2020 12:30PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Sep 15, 2020 08:11AM Exelixis (EXEL), Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
Sep 15, 2020 08:00AM Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
Sep 14, 2020 08:00AM Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
Sep 8, 2020 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
Sep 8, 2020 08:08AM Exelixis (EXEL) and Catalent (CTLT) Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag Bioconjugation Technology
Sep 8, 2020 08:07AM Exelixis (EXEL), NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Sep 8, 2020 08:05AM Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Sep 8, 2020 08:01AM Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
Aug 24, 2020 08:04AM Exelixis (EXEL) Announces Submission of sNDA to U.S. FDA for CABOMETYX in Combination With Opdivo for Advanced Renal Cell Carcinoma
Aug 24, 2020 08:00AM Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell
Aug 6, 2020 04:05PM Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 29, 2020 04:05PM Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Jul 20, 2020 08:06AM Exelixis (EXEL) Begins CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab in Previously Treated Metastatic RCC
Jul 20, 2020 08:00AM Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
Jun 30, 2020 08:00AM Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Jun 18, 2020 04:05PM Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020
Jun 11, 2020 08:03AM Exelixis (EXEL) Begins CONTACT-01 Ph. 3 Pivotal Trial of Cabozantinib in Combination w/ Atezolizumab in Previously Treated Metastatic NSCLC
Jun 11, 2020 08:00AM Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
Jun 3, 2020 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
May 13, 2020 05:05PM Exelixis (EXEL) Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
May 13, 2020 05:00PM Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
May 6, 2020 04:05PM Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
May 5, 2020 04:05PM Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
Apr 21, 2020 04:05PM Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020
Apr 20, 2020 07:10AM Bristol Myers Squibb (BMY), Exelixis (EXEL) Announce Positive Topline Results from Phase 3 CheckMate -9ER Trial Evaluating Opdivo in Combination with CABOMETYX in Previously Untreated RCC
Apr 20, 2020 06:59AM Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previous
Apr 8, 2020 04:05PM Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020
Mar 25, 2020 03:01AM Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
Mar 2, 2020 04:05PM Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors
Feb 26, 2020 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in March
Feb 25, 2020 04:06PM Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer
Feb 25, 2020 04:05PM Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Feb 12, 2020 04:05PM Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
Feb 10, 2020 05:01PM Exelixis (EXEL) Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic CRPC
Feb 10, 2020 05:00PM Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Feb 6, 2020 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in February
Jan 29, 2020 02:01AM Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma
Jan 24, 2020 07:30AM Exelixis (EXEL) Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in HCC
Jan 24, 2020 07:30AM Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
Jan 12, 2020 04:00PM Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
Jan 7, 2020 04:05PM Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
Jan 7, 2020 07:31AM Exelixis (EXEL) Reports Further Expansion of Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib
Jan 7, 2020 07:30AM Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Dec 19, 2019 07:05AM Exelixis (EXEL) Enters Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors
Dec 19, 2019 07:00AM Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors
Dec 13, 2019 06:16AM Exelixis (EXEL) Announces Positive Results From IMspire150 Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma
Dec 13, 2019 01:02AM Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma
View More Recent Stories View Older Stories